x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Flot.bio x Philip Hemme

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the

science life sciences

All Episodes

01:10:31

Claus Crone Fuglsang, Novonesis 🇩🇰 | Biosolutions,...

Flot.bio x Philip Hemme ·

2026/02/17

Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up.⭐️ ABOUT THE SPEAKERClaus first joined Novozymes in 1993 and led its R&D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA.🔗 LINKS MENTIONEDNovonesis’ website —

en-us

01:24:41

Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug...

Flot.bio x Philip Hemme ·

2026/02/09

At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: https://bit.ly/cereno-e52---⭐️ ABOUT THE SPEAKERSten joined Cereno as

en-us

01:00:42

Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis,...

Flot.bio x Philip Hemme ·

2026/02/02

Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breathe new life into generic drugs, making it easier for patients to stick to their treatment regimen. This has applications in many diseases, including hormonal disorders and obesity, with new formulations of GLP-1 agonists.He also discusses how long-acting versions of buprenorphine can

en-us

01:05:36

Alessandro Riva, Transgene | Cancer Vaccines,...

Flot.bio x Philip Hemme ·

2026/01/12

Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China.---Learn more about Transgene: https://bit.ly/tg_flotbio---⭐️ ABOUT THE SPEAKERAlessandro became Transgene’s CEO in 2023 after joining in 2022 as Chairman of the Board of Directors. He also played a key role in Gilead Sciences’ acquisition of Kite Pharma and the

en-us

01:14:33

Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49

Flot.bio x Philip Hemme ·

2026/01/06

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy. We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech

en-us

00:59:34

Werner Lanthaler 🇦🇹 | Biopharma AI, CDMO, Antibody...

Flot.bio x Philip Hemme ·

2025/12/01

Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sabbatical in 2024. We talk about his new missions as FairJourney CEO and founder of WLAN Holdings, and discuss the global CDMO scene and Europe’s competitivity in biotech.And while it's still early days yet, we find out AI will transform the way we work in biopharma going forward,

en-us

00:44:27

Thomas Lingelbach, Valneva | Vaccines, Lyme Disease |...

Flot.bio x Philip Hemme ·

2025/11/24

Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell

en-us

00:53:40

Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis,...

Flot.bio x Philip Hemme ·

2025/11/17

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.⭐️ ABOUT THE SPEAKERMarc de Garidel joined Abivax as CEO

en-us

00:50:03

Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles,...

Flot.bio x Philip Hemme ·

2025/11/10

As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure.⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including

en-us

01:24:33

Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy,...

Flot.bio x Philip Hemme ·

2025/10/29

As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing.Philip sits down with co-founder Gerrit Sitters to discuss the company’s trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam.---Explore how LUMICKS' technology helps develop

en-us

00:54:48

Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits,...

Flot.bio x Philip Hemme ·

2025/10/21

We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million. ⭐️ ABOUT THE SPEAKERFabrice Chouraqui has been the CEO of Pharming Group since

en-us

01:07:40

Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin...

Flot.bio x Philip Hemme ·

2025/10/13

Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue

en-us

01:08:49

Dragan Grabulovski, Araris 🇨🇭 | ADC Linkers,...

Flot.bio x Philip Hemme ·

2025/10/08

Philip meets up with Dragan Grabulovski, CEO of the startup Araris, at Lake Zurich to chat about the company’s work with antibody-drug conjugates (ADCs).They talk about Araris’ huge $400M upfront buyout by Taiho Pharma of Japan, Dragan’s extensive history as a biotech entrepreneur, and Araris’ vision to replace chemotherapy with ADCs.⭐️ ABOUT THE SPEAKERDragan Grabulovski is a co-founder of the startup Araris and became CEO in 2023. He previously worked as a biotech consultant and startup coach in

en-us

01:18:34

Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases,...

Flot.bio x Philip Hemme ·

2025/10/01

On a trip to Basel, Switzerland, Philip catches up with Stefano Portolano, CEO of the European firm Azafaros. They chat about Azafaros’ massive $147M Series B round in May 2025, which is being used to develop a small molecule treatment for rare diseases known as lysosomal storage disorders.Stefano also explains how rare diseases went in and out of fashion with big pharma, the revival of small molecule drugs relative to gene therapies and biologics, and his extensive experience in big biotech

en-us

00:58:02

Alex Zhavoronkov, Insilico Medicine | AI Drug...

Flot.bio x Philip Hemme ·

2025/09/24

We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.⭐️ ABOUT THE SPEAKERAlex founded Insilico in

en-us

00:58:22

Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London...

Flot.bio x Philip Hemme ·

2025/09/02

We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for

en-us

00:49:17

Aino Kalervo, TILT Biotherapeutics 🇫🇮 |...

Flot.bio x Philip Hemme ·

2025/07/14

We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its oncolytic virus candidate to supercharge cancer immunotherapies.We also explore the challenging space of oncolytic viruses and the untapped potential of biotech innovation in Finland.______For transparency,

en-us

00:53:46

Renee Aguiar-Lucander, Hansa Biopharma 🇸🇪 |...

Flot.bio x Philip Hemme ·

2025/06/30

Fresh after leading Calliditas Therapeutics through a $1.1B acquisition, Renee Aguiar-Lucander takes us through her new CEO role at Hansa Biopharma 🇸🇪.We learn how Hansa is commercialising Idefirix, its lead product for improving outcomes in kidney transplantation. We also cover the hot area of immunology, the behind-the-scenes story behind Calliditas’ takeover and the complex world of biotech financing.-----Launching a biotech startup? Grab your Biotech Starter Kit through Merck’s New Lab Starter

en-us

00:58:51

Stephane Bancel, Moderna | mRNA Therapeutics, Boston...

Flot.bio x Philip Hemme ·

2025/06/23

We’re with Stephane Bancel, CEO of the US mRNA giant Moderna. The company’s 15-year trajectory has taken it from the startup seed stage to a commercial heavyweight with three mRNA-based products in the market 🧬We go in-depth into Stephane’s leadership style and background before delving into Moderna’s research and the evolution of the mRNA space.⭐️ ABOUT THE SPEAKERStéphane Bancel joined mRNA therapeutics company Moderna as CEO in 2011 and led its efforts to develop a commercial COVID-19 vaccine

en-us

00:55:24

Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD,...

Flot.bio x Philip Hemme ·

2025/05/26

We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British roots of the company and why execution is the most important in biotech.⭐️ ABOUT THE SPEAKERChris Martin joined Verona Pharma as their COO in 2020. He’s

en-us

53 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter